Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Chronic Hepatitis C

In brief

The purpose of this study is to evaluate the safety, immunogenicity, and antiviral effects of multiple intravenous doses of ANZ-521 in patients with chronic Hepatitis C virus.

Key facts

Study ID

NCT00800007

Run by

Anza Therapeutics, Inc.

People needed

5

Starts

2008-11-01

Expected to finish

2009-02-01

Last updated by the study team

2009-02-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronic liver disease consistent with chronic hepatitis C infection, genotype 1, for at least 6 months
• For Part A only: patients who have had a full course of interferon and ribavirin as defined by the NIH Consensus Statement for the Management of Hepatitis C: 2002 (Management of hepatitis C: 2002, 2002) and have a detectable viral titer at Screening.
• For Part B only: patients who are HCV treatment-naïve with known contraindications (i.e., history of depression) to interferon and ribavirin combination therapy; patients who have started on interferon and ribavirin but stopped therapy early due to intolerance; patients who have not received interferon and ribavirin and have refused therapy
• Plasma HCV RNA viral titer of ≥ 2 logs above the assay cutoff measured at Screening.
• Females must be of non-child bearing potential [i.e., 1 year post menopausal or documented as being surgically sterile].
• Men must agree to use an acceptable form of birth control through the study and for 28 days after final dose of ANZ-521.
• Liver biopsy within the last 3 years with an Ishak Score <3 of FibroSURE test score <0.59.
• Compensated liver disease (Child-Pugh class A) with the adequate organ function as defined by study-specific laboratory tests.
• Signed Informed Consent and willing and able to comply with all study procedures.

You may not qualify if…

• Patients who are null responders to interferon-based therapy as defined by a less than 1-log decrease in viral titer from baseline during treatment.
• Treatment with anti-HCV therapy within one month prior to study.
• History of infection with Listeria.
• History of having received an experimental HCV vaccine (therapeutic or preventive).
• Known allergy to both penicillin and sulfa drugs, or component of the study drug product (e.g., glycerol).
• Current or prior history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical condition.
• Artificial (prosthetic) joint or other artificial implant or devices that cannot be easily removed.
• History of malignancy of any type, other than surgically excised non-melanomatous skin cancers or in situ cervical cancer within 5 years.
• Taking certain medications such as more than 2 g of acetaminophen per day, systemic antibiotics within 14 days of study entry, another investigational product within 28 days of study entry.
• Recent hospitalization or planned surgery requiring general anesthesia or sedation.
• Drug screen positive for cocaine.
• Positive for HIV or Hepatitis B antibodies.
• Blood donation of more than 450 mL within 8 weeks of study entry.
• Other condition that might affect the subject's ability to give informed consent or comply with study requirements.

Where it is running

• Advanced Clinical Research Institute — Anaheim, California, United States
• Alamo Medical Research — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.